Glasgow’s Chemify Secures €43M To Accelerate AI-driven Molecule Creation

The round was co-led by Wing Venture Capital and Insight Partners, with participation from 8VC and existing investors including Triatomic Capital, Blueyard, Rockspring, and Eos.

Wing Venture Capital supports ambitious founders, leading Seed and Series A rounds while providing hands-on expertise to build AI-driven businesses.

Ansuman Satpathy, a Partner at Wing Venture Capital, comments, “Chemify’s technology uses automation and physical AI to enable the digitisation of chemistry, transforming chemical synthesis from an art to a programmable science. We are excited to support the team’s progress as they empower scientists to create novel molecules with unmatched efficiency and precision. Their work has the potential to drive significant advancements in drug discovery and medicine.”

Read Also - Sizable Energy Secures $8M To Develop Offshore Energy Storage Solutions

Insight Partners is a global investor that backs high-growth technology, software, and internet startups and scale-ups, supporting companies that are driving transformative change across their industries.

Aiden Aceves, Vice President at Insight Partners, remarks, “Lee is an iconoclast with the wind at his back. Chemify’s use of AI to ensure the makeability of complex molecules is a paradigm shift for how medicinal chemistry is done today, and the company’s vision is matched by the strong results seen across their early pharma collaborations.”

The Series B funding will help Chemify expand globally through digital chemistry hubs, offering on-demand molecule design and manufacturing for pharmaceutical, biotech, and materials science partners.

The Scottish company will open a Silicon Valley facility led by CTO Mike Bell, boosting its ability to rapidly develop molecules and set a new standard in small-molecule creation.

As part of the round, Ansuman Satpathy (Wing Venture Capital) and Aiden Aceves (Insight Partners) have joined Chemify’s Board of Directors.

Founded in 2022 as a University of Glasgow spin-out by Lee Cronin, Chemify is transforming how molecules for medicines and materials are discovered and made.

The company’s Chemputation platform combines AI and robotics to turn digital designs into physical compounds. Its first Chemifarm, a 21,500 sq ft fully automated lab in Glasgow’s Maryhill, integrates AI-driven molecular design with robotic synthesis to accelerate small-molecule development.

The facility features R&D labs, production suites, engineering zones, and secure cloud storage for petabytes of chemical data, enabling design, optimization, scaling, and prototyping of next-generation Chemifarm hardware for global expansion.

“Chemify aims to become the global digital backbone of chemistry, enabling fast design and discovery,” says Lee Cronin, CEO and Founder, Chemify.

“Our vision is that Chemify will be able to design and make any molecule on demand for our customers across all of chemistry, from drug discovery to new catalysts and electronic materials. The next step in our evolution is nothing short of a revolution in the digitisation and automation of chemical discovery and manufacturing,” adds Cronin.

About Chemify

Chemify Limited is revolutionizing molecular discovery by digitizing chemistry. Using its Chemputation platform, the company transforms digital code into physical molecules and vice versa, combining AI and robotics to accelerate the design, optimization, and production of new medicines and advanced materials, setting a new standard for chemical innovation.